Sign In
Buy PHGE
$0.184
-0.0046 (-2.44%)
At Close: Jul 31, 2026
BiomX Announces Dosing of First Subject in Phase 1a Study of BX002 Phage Therapy for Inflammatory Bowel Disease
06:30am, Wednesday, 04'th Nov 2020
NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE), a clinical stage company developing natural and engineered phage therapies that target specific pathogenic bacteria, today announ
